Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.

Vincent Grigori NguyenAlexei YavlinskySarah BealeSusan HoskinsThomas E ByrneVasileios LamposIsobel BraithwaiteWing Lam Erica FongEllen FragaszyCyril GeismarJana KovarAnnalan M D NavaratnamParth PatelMadhumita ShrotriSophie WeberAndrew C HaywardRobert W Aldridge

Published in: International journal of epidemiology (2023)

After an mRNA booster dose, we found no difference in protection comparing those with a primary course of BNT162b2 with those with a ChAdOx1 primary course. This contrasts with pre-booster findings where previous research shows greater effectiveness of BNT162b2 than ChAdOx1 in preventing infection.

Keyphrases

sars cov
randomized controlled trial
healthcare
systematic review
clinical trial
study protocol
mental health
binding protein
phase iii
open label
disease virus